RAP-219 is a clinical-stage AMPA receptor negative allosteric modulator, designed to treat focal epilepsy and other CNS disorders. What were the results of the PET and MAD-2 trials for RAP-219?
AMPA receptors are present throughout the brain ... as a potentially differentiated treatment for patients with focal epilepsy, diabetic peripheral neuropathic pain, and bipolar mania.
Additionally, the data provide further support for the dosing regimen selected for our ongoing Phase 2a trial in focal epilepsy ... TARPγ8 associated AMPA receptors to significantly enhance ...
A Phase 2a proof-of-concept trial is currently underway to evaluate RAP-219 in patients with refractory focal epilepsy, with topline results expected in mid-2025. RAP-219 is a clinical-stage AMPA ...
Additionally, the data provide further support for the dosing regimen selected for our ongoing Phase 2a trial in focal epilepsy ... evidence of selectively targeting TARPγ8 associated AMPA receptors ...
A new international study has unveiled critical insights in understanding post-traumatic epilepsy (PTE), a condition that can ...
Published in Theranostics, the study highlights the important role played by a receptor in the brain called P2X7. It suggests how we could both reduce epilepsy risk and predict which patients are ...
Although scientists can learn a lot from cell culture and animal models, they cannot truly substitute for all parts of the ...